J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma
XTalks
APRIL 11, 2024
Carvykti’s approval was based on data from the Phase III CARTITUDE-4 study that showed earlier use of Carvykti cut the risk of disease progression or death by 59 percent compared to standard therapy combinations in adults with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy.
52 
Let's personalize your content